文献速递皮肤肿瘤

预测复杂莫氏显微手术的REGESMOSH量表开发与验证

Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-03-23

基于西班牙莫氏手术注册研究(REGESMOHS)的前瞻性队列,纳入4402例基底细胞癌患者,构建并验证预测莫氏显微手术需≥3个阶段及复杂闭合的模型(REGESMOSH量表)。预测≥3阶段的模型纳入肿瘤尺寸、免疫抑制、复发、风险部位、组织学侵袭性和既往手术;预测复杂闭合的模型纳入组织学侵袭性、演变时间、年龄、最大肿瘤尺寸和部位。该模型可优化手术安排并向患者告知手术时长。

要点

  • REGESMOSH量表基于4402例基底细胞癌莫氏手术数据开发并验证。
  • 预测≥3个阶段的模型含肿瘤尺寸、免疫抑制、复发、风险部位、组织学侵袭性、既往手术。
  • 预测复杂闭合的模型含组织学侵袭性、演变时间、年龄、最大肿瘤尺寸和部位。

核心结论

  • 研究提出并验证了预测莫氏显微手术需≥3个阶段及需复杂闭合的模型,基于大型人群数据且涵盖不同中心,可较容易地应用于临床实践。
  • 该模型可用于优化手术安排并向患者恰当告知手术时长。

研究设计与样本

  • 全国性前瞻性队列研究(REGESMOHS,西班牙莫氏手术注册研究),纳入所有组织学诊断为基底细胞癌的患者。
  • 共纳入5226例接受莫氏显微手术的患者,其中4402例(84%)组织学诊断为基底细胞癌。
  • 探索与≥3个阶段及复杂闭合(需皮瓣和/或移植物)相关的因素,构建并验证预测模型以形成REGESMOSH量表。

主要发现

  • 3689例(88.9%)手术仅需1或2个阶段,460例(11.1%)需要3个或更多阶段。
  • 1616例(38.8%)手术采用非复杂闭合技术,2552例(61.2%)需要复杂闭合。
  • 预测需≥3个阶段的模型包括肿瘤尺寸、免疫抑制、复发、位于风险区域、组织学侵袭性和既往手术。
  • 预测需复杂闭合的模型包括组织学侵袭性、演变时间、患者年龄、最大肿瘤尺寸和部位。

关键数值与推荐

  • 预测需≥3个阶段的模型纳入因素:肿瘤尺寸、免疫抑制、复发、位于风险区域、组织学侵袭性、既往手术。
  • 预测需复杂闭合的模型纳入因素:组织学侵袭性、演变时间、患者年龄、最大肿瘤尺寸、部位。

临床怎么用

  • 作者认为该模型可用于优化手术安排并向患者恰当告知手术时长。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is still a need to develop a simple algorithm to identify patients likely to need complex Mohs micrographic surgery (MMS) and optimize MMS schedule. The main objectives of this study are to identify factors associated with a complex MMS and develop a predictor model of the number of stages needed in surgery and the need for a complex closure. MATERIALS AND METHODS: A nationwide prospective cohort study (REGESMOHS, the Spanish Mohs surgery registry) was conducted including all patients with a histological diagnosis of basal cell carcinoma (BCC). Factors related to three or more stages and a complex closure (that needing a flap and/or a graft) were explored and predictive models were constructed and validated to construct the REGESMOSH scale. RESULTS: A total of 5226 patients that underwent MMS were included in the REGESMOHS registry, with 4402 (84%) having a histological diagnosis of BCC. A total of 3689 (88.9%) surgeries only needed one or two stages and 460 (11.1%) required three or more stages. A model to predict the need for three or more stages included tumour dimension, immunosuppression, recurrence, location in risk areas, histological aggressiveness and previous surgery. Regarding the closure type, 1616 (38.8%) surgeries were closed using a non-complex closure technique and 2552 (61.2%) needed a complex closure. A model to predict the need for a complex closure included histological aggressiveness, evolution time, patient age, maximum tumour dimension and location. CONCLUSION: We present a model to predict MMS needing ≥3 stages and a complex closure based on epidemiological and clinical data validated in a large population (with real practice variability) including different centres that could be easily implemented in clinical practice. This model could be used to optimize surgery schedule and properly inform patients about the surgery duration.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Montero-Vilchez T, Garcés JR, Rodríguez-Prieto MA, et al. Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale. J Eur Acad Dermatol Venereol. 2023. PMID: 36950898. doi:10.1111/jdv.19056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。